Home  »  Companies   »  Is Day One Biopharmaceuticals Inc. (DAWN) a Keeper...

Is Day One Biopharmaceuticals Inc. (DAWN) a Keeper?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) went down by -7.62% from its latest closing price compared to the recent 1-year high of $28.70. The company’s stock price has collected -13.79% of loss in the last five trading sessions. Press Release reported on 01/05/22 that Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference

Is It Worth Investing in Day One Biopharmaceuticals Inc. (NASDAQ :DAWN) Right Now?

Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Day One Biopharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $35.00, which is $20.81 above the current price. DAWN currently public float of 41.42M and currently shorts hold a 8.31% ratio of that float. Today, the average trading volume of DAWN was 187.59K shares.

DAWN’s Market Performance

DAWN stocks went down by -13.79% for the week, with a monthly drop of -18.68% and a quarterly performance of -36.65%. The volatility ratio for the week stands at 9.95% while the volatility levels for the past 30 days are set at 8.05% for Day One Biopharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -14.19% for DAWN stocks with a simple moving average of -34.72% for the last 200 days.

DAWN Trading at -24.67% from the 50-Day Moving Average

After a stumble in the market that brought DAWN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.56% of loss for the given period.

Volatility was left at 8.05%, however, over the last 30 days, the volatility rate increased by 9.95%, as shares sank -22.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.83% lower at present.

During the last 5 trading sessions, DAWN fell by -13.79%, in comparison to the 20-day moving average, which settled at $16.33. In addition, Day One Biopharmaceuticals Inc. saw -15.79% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DAWN starting from Blackman Samuel C., who sale 10,000 shares at the price of $17.10 back on Jan 03. After this action, Blackman Samuel C. now owns 1,366,718 shares of Day One Biopharmaceuticals Inc., valued at $171,018 using the latest closing price.

TAKEDA PHARMACEUTICAL CO LTD, the 10% Owner of Day One Biopharmaceuticals Inc., sale 110,338 shares at $18.03 during a trade that took place back on Dec 08, which means that TAKEDA PHARMACEUTICAL CO LTD is holding 6,120,124 shares at $1,989,394 based on the most recent closing price.

Stock Fundamentals for DAWN

The total capital return value is set at -39.84, while invested capital returns managed to touch -140.18.

Based on Day One Biopharmaceuticals Inc. (DAWN), the company’s capital structure generated 1.06 points at debt to equity in total, while total debt to capital is 1.05.

>> 7 Top Picks for the Post-Pandemic Economy <<

The liquidity ratio also appears to be rather interesting for investors as it stands at 22.58.

Leave a Comment

Your email address will not be published. Required fields are marked *




Download Free eBook For


100% free. stop anytime no spam